CMMB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMMB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Chemomab Therapeutics's Operating Income for the three months ended in Mar. 2025 was $-3.49 Mil. Chemomab Therapeutics's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Chemomab Therapeutics Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Chemomab Therapeutics's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Chemomab Therapeutics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Chemomab Therapeutics Annual Data | |||||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||
Interest Coverage | N/A | - | N/A | N/A | N/A |
Chemomab Therapeutics Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Interest Coverage | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
N/A | N/A | N/A | N/A | N/A |
For the Biotechnology subindustry, Chemomab Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Chemomab Therapeutics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Chemomab Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as
Here, for the fiscal year that ended in Dec. 2024, Chemomab Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-14.74 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.21 Mil.
GuruFocus does not calculate Chemomab Therapeutics's interest coverage with the available data. |
Chemomab Therapeutics's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as
Here, for the three months ended in Mar. 2025, Chemomab Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-3.49 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.18 Mil.
GuruFocus does not calculate Chemomab Therapeutics's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
Chemomab Therapeutics (NAS:CMMB) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of Chemomab Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Orbimed Israel Biofund Gp Limited Partnership | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
George Adi Mor | director, 10 percent owner, officer: Chief Executive Officer | 15 KAFRISIN ST., TEL AVIV L3 6901658 |
Neil Harris Cohen | director | C/O ANCHIANO THERAPEUTICS LTD., ONE KENDALL SQ., BLDG 1400E, STE 14-105, CAMBRIDGE MA 02139 |
Matthew Bejosa Frankel | officer: Chief Medical Officer | 672 PROSPECT AVE., PRINCETON NJ 08540 |
Jill M. Quigley | director | TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103 |
Joel Michael Maryles | director | 5 ATZMON ST., HASHMONAIM L3 7312700 |
Donald Marvin | officer: Executive VP, CFO & COO | 2094 LOST CANYON RANCH CT, CASTLE ROCK CO 80104 |
Dale R Pfost | director, officer: Chief Executive Officer | ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104 |
Nissim Darvish | director | C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Peter Thiel | 10 percent owner | 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069 |
Sigal Fatal | officer: Chief Financial Officer | 16 KANFEY NESHARIM ST., RAMAT GAN L3 5235716 |
Arnon Aharon | officer: Chief Medical Officer | 12 YAVNE ST., TEL AVIV L3 6579116 |
Alan Charles Moses | director | C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Stephen P Squinto | director | C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Orbimed Israel Gp Ltd. | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629 |
From GuruFocus
By Marketwired • 08-12-2024
By Marketwired • 10-30-2024
By Marketwired • 02-19-2025
By GuruFocus News • 04-15-2025
By Marketwired • 04-21-2025
By Marketwired • 06-06-2024
By Marketwired • 03-06-2025
By Marketwired • 03-27-2025
By Marketwired • 07-25-2024
By Marketwired • 08-28-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.